Provigil.com | References

References

View Patient Information for PROVIGIL.

View Full Prescribing Information for PROVIGIL.

PDF requires Adobe^® Reader^®

IMS HEALTH's National Prescription Audit Plus™ (February 1999-October 2007).
Lee-Chiong TL. Manifestations and classifications of sleep disorders. In: Lee-Chiong TL, Sateia MJ, Carskadon MA, eds. Sleep Medicine. Philadelphia, PA: Hanley & Belfus, Inc.; 2005:125-141.
National Institutes of Health, National Institute of Neurological Disorders and Stroke. Brain Basics: Understanding Sleep. Bethesda, MD: National Institutes of Health; 2007. NIH Publication 06-3440-c.
American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester, IL. American Academy of Sleep Medicine; 2005.
Carney PR, Berry RB, Geyer JD. Clinical Sleep Disorders. Philadelphia, PA: Lippincott Williams & Wilkens; 2005:255.
Attarian HP, Sabri AN. When to suspect obstructive sleep apnea syndrome. Postgrad Med. 2002;111(3). http://www.postgradmed.com/issues/2002/03_02/attarian.shtml. Accessed March 7, 2008.
Schwartz AR, Patil SP, Laffan AM, et al. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc. 2008;5(2):185-192.
Naughton MT. The link between obstructive sleep apnea and heart failure: underappreciated opportunity for treatment. Curr Heart Fail Rep. 2006;3(4):183-188.
Aldrich MS. Sleep Medicine. New York, NY: Oxford University Press, Inc; 1999.
Sanders MH, Givelber RJ. Overview of obstructive sleep apnea in adults. In: Lee-Chiong TL, ed. Sleep: A Comprehensive Handbook. Hoboken, NJ: John Wiley & Sons, Inc. 2006:231-240.
Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007;30(6):711-719.
Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000;118(2):372-379.
Reishstein JL, Pack AI, Maislin G, et al. Sleepiness and relationships in obstructive sleep apnea. Issues Ment Health Nurs. 2006;27(3):319-330.
United States Department of Labor, Bureau of Labor Statistics Web site. Workers on flexible and shift schedules in May 2004. http://www.bls.gov/news.release/pdf/flex.pdf. Accessed March 5, 2008.
Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep. 2004;27(8):1453-1462.
Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476-486.
American Academy of Sleep Medicine (AASM) — Narcolepsy Fact Sheet. http://www.aasmnet.org/Resources/FactSheets/Narcolepsy.pdf. Accessed March 19, 2008.
National Institute of Neurological Disorders and Stroke (NINDS) — Narcolepsy Fact Sheet. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm. Accessed April 16, 2008.
US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43(1):88-97.
Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep. 2001;24(4):451-466.
Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540-545.

Important Safety Information for PROVIGIL

PROVIGIL is a prescription medicine used to improve wakefulness in adults who experience excessive sleepiness (ES) due to one of the following diagnosed sleep disorders: obstructive sleep apnea (OSA), shift work sleep disorder (SWSD), or narcolepsy.

In patients with OSA, PROVIGIL is used along with other medical treatments for this sleep disorder. PROVIGIL is not a replacement for your current treatment. Consult your doctor about the importance of continuing your current OSA treatment while taking PROVIGIL.

PROVIGIL may cause you to have a serious rash or a serious allergic reaction that may result in hospitalization or be life-threatening. If you develop a rash, hives, sores, swelling, or trouble swallowing or breathing, stop taking PROVIGIL and call your doctor right away or get emergency treatment.

PROVIGIL is not approved for use in children.

If you experience chest pain, depression, anxiety, hallucinations, psychosis, mania, thoughts of suicide, aggression, or other mental problems, stop taking PROVIGIL and call your doctor right away or get emergency treatment.

PROVIGIL does not replace sleep and may not stop your ES completely. Do not drive or do other dangerous activities until you know how PROVIGIL affects you. Avoid drinking alcohol while taking PROVIGIL.

PROVIGIL has the potential to be abused or lead to dependence. Please use only as directed.

Tell your doctor if you have: history of mental health problems (including psychosis), heart problems or had a heart attack, high blood pressure, liver or kidney problems, a history of drug or alcohol abuse or addiction, or are pregnant, planning to become pregnant, or breastfeeding.

Women who use hormonal birth control may have a higher chance of getting pregnant, while taking PROVIGIL, and for one month after stopping. Talk to your doctor about other birth control methods while taking PROVIGIL.

Common side effects of PROVIGIL are headache, nausea, nervousness, stuffy nose, diarrhea, back pain, anxiety, trouble sleeping, dizziness, and upset stomach.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For more information, ask your doctor, or call 1-800-896-5855.

This information does not take the place of talking with your doctor about your condition or treatment.

Please see the Patient Information in the Full Prescribing Information for PROVIGIL.